Evidence map›Paper›PMID 33796452›Full record

ArticleFrontiers in oncology2021

Assessment of CPS + EG, Neo-Bioscore and Modified Neo-Bioscore in Breast Cancer Patients Treated With Preoperative Systemic Therapy: A Multicenter Cohort Study.

Ling Xu, Yinhua Liu, Zhimin Fan, Zefei Jiang, Yunjiang Liu, Rui Ling, Jianguo Zhang, Zhigang Yu, Feng Jin, Chuan Wang and 24 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03437837 (Validation of CPS+EG, Neo-Bioscore and Modified Neo-Bioscore Staging System After Preoperative Systemic Therapy of Breast Cancer in Multi-center in China), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03437837 completednot on this map

Validation of CPS+EG, Neo-Bioscore and Modified Neo-Bioscore Staging System After Preoperative Systemic Therapy of Breast Cancer in Multi-center in China

TypeobservationalSponsorPeking University First HospitalRan2017 to 2018Enrolled1,077ConditionsBreast Cancer, Neoadjuvant Therapy, Neoplasm Staging, Estrogen Receptor
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Ling XuBreast Disease Center, Peking University First Hospital, Beijing, China.
Yinhua LiuBreast Disease Center, Peking University First Hospital, Beijing, China.
Zhimin FanDepartment of Breast Surgery, First Hospital of Jilin University, Changchun, China.
Zefei JiangDepartment of Breast Cancer, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, China.
Yunjiang LiuHebei Breast Cancer Center, The 4th Hospital of Hebei Medical University, Shijiazhuang, China.
Rui LingDepartment of Thyroid, Breast and Vascular Surgery, Xijing Hospital, Air Force (Military) Medical University, Xi'an, China.
Jianguo ZhangBreast Disease Department, Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Zhigang YuDepartment of Breast Surgery, Second Hospital of Shandong University, Jinan, China.
Feng JinDepartment of Breast Surgery, The First Hospital of China Medical University, Shenyang, China.
Chuan WangDepartment of Breast Surgery, Affiliated Union Hospital of Fujian Medical University, Fuzhou, China.
Shude CuiDepartment of Breast Surgery, Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou, China.
Shu WangBreast Center, Peking University People's Hospital, Beijing, China.
Dahua MaoDepartment of Breast Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Bing HanDepartment of Breast Surgery, First Hospital of Jilin University, Changchun, China.
Tao WangDepartment of Breast Cancer, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, China.
Geng ZhangHebei Breast Cancer Center, The 4th Hospital of Hebei Medical University, Shijiazhuang, China.
Ting WangDepartment of Thyroid, Breast and Vascular Surgery, Xijing Hospital, Air Force (Military) Medical University, Xi'an, China.
Baoliang GuoBreast Disease Department, Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Lixiang YuDepartment of Breast Surgery, Second Hospital of Shandong University, Jinan, China.
Yingying XuDepartment of Breast Surgery, The First Hospital of China Medical University, Shenyang, China.
Fangmeng FuDepartment of Breast Surgery, Affiliated Union Hospital of Fujian Medical University, Fuzhou, China.
Zhenzhen LiuDepartment of Breast Surgery, Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou, China.
Siyuan WangBreast Center, Peking University People's Hospital, Beijing, China.
Ke LuoDepartment of Breast Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Qian XiangDepartment of Pharmacy, Peking University First Hospital, Beijing, China.
Zhuo ZhangDepartment of Pharmacy, Peking University First Hospital, Beijing, China.
Qianxin LiuDepartment of Pharmacy, Peking University First Hospital, Beijing, China.
Bin ZhouBreast Disease Center, Peking University First Hospital, Beijing, China.
Zhaorui LiuInstitute of Mental Health, Peking University, Beijing, China.
Chao MaInstitute of Mental Health, Peking University, Beijing, China.
Weiwei TongGennlife (Beijing) Technology Co., Ltd, Beijing, China.
Jie MaoGennlife (Beijing) Technology Co., Ltd, Beijing, China.
Xuening DuanBreast Disease Center, Peking University First Hospital, Beijing, China.
Yimin CuiDepartment of Pharmacy, Peking University First Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study was to assess the prognosis stratification of the clinical-pathologic staging system incorporating estrogen receptor (ER)-negative disease, the nuclear grade 3 tumor pathology (CPS + EG), Neo-Bioscore, and a modified Neo-Bioscore system in breast cancer patients after preoperative systemic therapy (PST). A retrospective multicenter cohort study was conducted from 12 participating hospitals' databases from 2006 to 2015. Five-year disease free survival (DFS), disease specific survival (DSS), and overall survival (OS) were calculated using Kaplan-Meier Method. Area under the curve (AUC) of the three staging systems was compared. Wald test and maximum likelihood estimates in Cox proportional hazards model were used for multivariate analysis. A total of 1,077 patients were enrolled. The CPS + EG, Neo-Bioscore, and modified Neo-Bioscore could all stratify the DFS, DSS, and OS (all P < 0.001). While in the same stratum of Neo-Bioscore scores 2 and 3, the HER2-positive patients without trastuzumab therapy had much poorer DSS (P = 0.013 and P values < 0.01, respectively) as compared to HER2-positive patients with trastuzumab therapy and HER2-negative patients. Only the modified Neo-Bioscore had a significantly higher stratification of 5-year DSS than PS (AUC 0.79 CLINICAL

trial registrationClinicalTrials.gov, identifier NCT03437837.

Indexed as

breast cancer prognosisCPS + EGHER2Neo-Bioscorepreoperative systemic therapy

Identifiers

PMID33796452
PMCPMC8009183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.